Zoetis said revenue for Q2 2024 rose to $2.4 billion, up 8% from a year earlier, while net income fell 7% to $624 million, or $1.37 per diluted share, a decline of 6%. Operational revenue growth was 11%.

1. 01

   Zoetis said revenue for Q2 2024 rose to $2.4 billion, up 8% from a year earlier, while net income fell 7% to $624 million, or $1.37 per diluted share, a decline of 6%. Operational revenue growth was 11%.

2. 02

   The company said adjusted net income for Q2 was $711 million, or $1.56 per diluted share, up 9% on a reported basis and 11% on an operational basis. It said the net effect of purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items excluded from adjusted results was $87 million.

3. 03

   The company said revenue in its U.S. segment for Q2 rose 12% to $1.3 billion, while International segment revenue was $1.0 billion, up 4% on a reported basis and 10% operationally. It cited Librela and Solensia, among other products, as drivers of the 13% increase in U.S. companion animal product sales.

4. 04

   The company raised its full-year 2024 revenue guidance to $9.100 to $9.250 billion. It gave reported diluted EPS guidance of $5.35 to $5.45 and adjusted diluted EPS guidance of $5.78 to $5.88. The company said the outlook reflects foreign exchange rates as of late July.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.